Gilead presents Biktarvy findings from switch studies & analysis of real-world BICSTaR study at HIV Glasgow 2020.
Gilead Sciences, Inc. announced long-term study results , which showed that people living with HIV who switched to the once-daily, single tablet regimen, Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) from a boosted protease inhibitor-based regimen consisting of atazanavir (ATV) or darunavir (DRV) plus either emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) or abacavir (ABC)/lamivudine (3TC) maintained virologic suppression (defined as HIV-1 RNA less than 50 copies/mL) with no emergent resistance, through a maximum of 156 weeks.